These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24516631)

  • 1. Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012.
    Wang J; He C; Hsi JH; Xu X; Liu Y; He J; Ling H; Ding P; Tong Y; Zou X; Zhou Q; Liao L; Wang X; Ruan Y; Shao Y; Xing H
    PLoS One; 2014; 9(2):e88305. PubMed ID: 24516631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
    Wang J; Wang Z; Liu J; Yue Y; Yang S; Huang H; He C; Liao L; Xing H; Ruan Y; Shao Y
    Sci Rep; 2015 Oct; 5():14823. PubMed ID: 26445885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study.
    Kan W; Teng T; Liang S; Ma Y; Tang H; Zuohela T; Sun G; He C; Wall KM; Marconi VC; Liao L; Leng X; Liu P; Ruan Y; Xing H; Shao Y
    BMJ Open; 2017 Sep; 7(9):e016012. PubMed ID: 28882911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China.
    Leng X; Liang S; Ma Y; Dong Y; Kan W; Goan D; Hsi JH; Liao L; Wang J; He C; Zhang H; Xing H; Ruan Y; Shao Y
    BMJ Open; 2014 Oct; 4(10):e005886. PubMed ID: 25319999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
    Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S
    Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients on second line antiretroviral therapy under programmatic condition in India.
    Chakravarty J; Sundar S; Chourasia A; Singh PN; Kurle S; Tripathy SP; Chaturbhuj DN; Rai M; Agarwal AK; Mishra RN; Paranjape RS
    BMC Infect Dis; 2015 Nov; 15():517. PubMed ID: 26572102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
    Mancinelli S; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Amici R; Pirillo MF; Scarcella P; Marazzi MC; Vella S; Palombi L; Giuliano M
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):737-42. PubMed ID: 27067142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
    Hosseinipour MC; Kumwenda JJ; Weigel R; Brown LB; Mzinganjira D; Mhango B; Eron JJ; Phiri S; van Oosterhout JJ
    HIV Med; 2010 Sep; 11(8):510-8. PubMed ID: 20345885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.
    Johannessen A; Naman E; Kivuyo SL; Kasubi MJ; Holberg-Petersen M; Matee MI; Gundersen SG; Bruun JN
    BMC Infect Dis; 2009 Jul; 9():108. PubMed ID: 19583845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
    Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
    J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.